EMEA-001191-PIP01-11-M03
Key facts
| Invented name |
Daklinza
|
| Active substance |
Daclatasvir
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0367/2019
|
| PIP number |
EMEA-001191-PIP01-11-M03
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of chronic hepatitis C
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|